Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lantheus ( (LNTH) ) has provided an update.
On November 6, 2025, Lantheus announced a leadership transition with CEO Brian Markison retiring effective December 31, 2025, and Mary Anne Heino appointed as Executive Chair and Interim CEO. The company reported third-quarter 2025 financial results, including a revenue of $384 million and a decrease in net income, while also highlighting strategic initiatives such as the acquisition of Life Molecular Imaging and the advancement of its radiopharmaceutical pipeline.
The most recent analyst rating on (LNTH) stock is a Hold with a $63.00 price target. To see the full list of analyst forecasts on Lantheus stock, see the LNTH Stock Forecast page.
Spark’s Take on LNTH Stock
According to Spark, TipRanks’ AI Analyst, LNTH is a Neutral.
Lantheus’ overall stock score is driven by solid financial performance and reasonable valuation. However, the lowered financial outlook and challenges in key product sales negatively impact the score. Technical indicators suggest mixed momentum, with short-term bullishness but longer-term caution.
To see Spark’s full report on LNTH stock, click here.
More about Lantheus
Lantheus Holdings, Inc. is a leading company in the radiopharmaceutical industry, focused on enabling clinicians to find, fight, and follow diseases to improve patient outcomes. The company specializes in diagnostic imaging agents and therapeutic products, with a significant emphasis on prostate cancer diagnostics and neuroendocrine tumors.
Average Trading Volume: 1,601,809
Technical Sentiment Signal: Sell
Current Market Cap: $3.92B
For an in-depth examination of LNTH stock, go to TipRanks’ Overview page.